B7IG fusion protein

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5580756
SERIAL NO

08219518

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C.gamma.1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • BRISTOL-MYERS SQUIBB COMPANY

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brady, William Bothell, WA 52 2338
Damle, Nitin K Renton, WA 36 1670
Ledbetter, Jeffrey A Seattle, WA 131 6909
Linsley, Peter S Seattle, WA 87 3624

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation